For research use only. Not for therapeutic Use.
Cefmetazole（Cat No.:I003075）is a broad-spectrum, second-generation cephalosporin antibiotic used to treat infections caused by Gram-positive and Gram-negative bacteria. It works by inhibiting bacterial cell wall synthesis, leading to cell lysis and bacterial death. Cefmetazole is commonly prescribed for infections such as skin and soft tissue infections, respiratory tract infections, and urinary tract infections. It is typically administered intravenously or intramuscularly in a hospital setting. Its stable β-lactam ring structure ensures effectiveness against β-lactamase-producing organisms. Cefmetazole offers a useful treatment option for a variety of bacterial infections.
| Catalog Number | I003075 |
| CAS Number | 56796-20-4 (free) |
| Synonyms | Cefmetazole; Cefmetazolo; Cefmetazolum; Cefmetazolum; Cefmetazolo; Sodium, Cefmetazole; U 72791A; U-72791A; U72791A; Zefazone; CS 1170; CS-1170; CS1170; Monosodium Salt, Cefmetazole; Pharmacia Brand of Cefmetazole Sodium; Salt, Cefmetazole Monosodium |
| Molecular Formula | C15H17N7O5S3 |
| Purity | ≥95% |
| Target | Antibiotic |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term or -20 °C for long term |
| IUPAC Name | (6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| InChI | InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1 |
| InChIKey | SNBUBQHDYVFSQF-HIFRSBDPSA-N |
| SMILES | CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O |
| Reference | </br>1:Optimal dosage of cefmetazole for intraoperative antimicrobial prophylaxis in patients undergoing surgery for colorectal cancer. Tomizawa A, Nakamura T, Komatsu T, Inano H, Kondo R, Watanabe M, Atsuda K.J Pharm Health Care Sci. 2017 Jan 7;3:1. doi: 10.1186/s40780-016-0071-6. eCollection 2017. PMID: 28074152 Free PMC Article</br>2:Cefmetazole for bacteremia caused by ESBL-producing enterobacteriaceae comparing with carbapenems. Fukuchi T, Iwata K, Kobayashi S, Nakamura T, Ohji G.BMC Infect Dis. 2016 Aug 18;16(1):427. doi: 10.1186/s12879-016-1770-1. PMID: 27538488 Free PMC Article</br>3:In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S.Diagn Microbiol Infect Dis. 2016 Apr;84(4):322-7. doi: 10.1016/j.diagmicrobio.2015.12.001. Epub 2015 Dec 11. PMID: 26782634 </br>4:Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S.Antimicrob Agents Chemother. 2015 Sep;59(9):5107-13. doi: 10.1128/AAC.00701-15. Epub 2015 Jun 22. PMID: 26100708 Free PMC Article</br>5:Non-cytotoxic nanomaterials enhance antimicrobial activities of cefmetazole against multidrug-resistant Neisseria gonorrhoeae. Li LH, Yen MY, Ho CC, Wu P, Wang CC, Maurya PK, Chen PS, Chen W, Hsieh WY, Chen HW.PLoS One. 2013 May 21;8(5):e64794. doi: 10.1371/journal.pone.0064794. Print 2013. PMID: 23705013 Free PMC Article</br>6:The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Doi A, Shimada T, Harada S, Iwata K, Kamiya T.Int J Infect Dis. 2013 Mar;17(3):e159-63. doi: 10.1016/j.ijid.2012.09.010. Epub 2012 Nov 8. PMID: 23140947 Free Article</br>7:Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole. Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, Hosoya K.Fluids Barriers CNS. 2011 Oct 21;8:24. doi: 10.1186/2045-8118-8-24. PMID: 22014165 Free PMC Article</br>8:[The clinical efficacy and safety of intravenous cefmetazole in treatment of 1,522 patients with aspiration pneumonia]. Zhang XY, Li Q, Zhou X.Zhonghua Nei Ke Za Zhi. 2011 Apr;50(4):295-8. Chinese. PMID: 21600147 </br>9:Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry. Fukutsu N, Sakamaki Y, Kawasaki T, Saito K, Nakazawa H.Chem Pharm Bull (Tokyo). 2006 Oct;54(10):1469-72. PMID: 17015995 Free Article</br>10:LC/MS/MS method for the determination of trace amounts of cefmetazole and cefpodoxime proxetil contaminants in pharmaceutical manufacturing environments. Fukutsu N, Sakamaki Y, Kawasaki T, Saito K, Nakazawa H.J Pharm Biomed Anal. 2006 Jun 16;41(4):1243-50. Epub 2006 May 15. PMID: 16704914 |
